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Introduction: The molecular events occurring within the human
kidney during treatment of lupus nephritis (LN) are unknown. We
previously reported that the immune proﬁle of LN biopsies at ﬂare
is different between complete responders (CR) from non- re-
sponders (NR). Here, we evaluate whether the differences in renal
transcript expression after induction therapy can distinguish bi-
opsies that end in CR and NR and identify a set of markers asso-
ciated with treatment response and non-response.
Methods: The expression of 511 immune-response genes was
determined in kidney biopsies from 19 patients with proliferative
LN and 4 normal controls using Nanostring technology. Biopsies
were done at ﬂare (Bx1) and after induction therapy (Bx2). After
induction, 5 patients achieved CR, 4 patients had an NR and 10
patients achieved a PR by clinical metrics (24 hour urine protein-
uria and serum creatinine).
Results: Transcript expression was measured at Bx1 and Bx2 in all
patients and compared to normal controls. Additionally, the change
in expression from Bx1 and Bx2 was compared within each group
and between groups. Transcripts were considered differentially
expressed if they achieved both a p-value of <0.05 and at least a 1.5
fold change. From Bx1 to Bx2, transcripts that signiﬁcantly
changed in ﬂares that ended in CR included increased expression of
NCAM1 (FC-2.24, P¼0.004), and decreased expression of IL1RL1
(FC: -3.13, P¼0.001), FKBP5 (FC: -4.76, P¼0.009), FCAR (FC: -2.04,
P¼0.011), and IL17 (FC: -1.7, P¼0.018).
Transcript expression analysis in ﬂares that ended in NR iden-
tiﬁed an 11-gene signature including increased expression of IL17
(FC: 1.66, P¼0.044), IL1RAP (FC: 2.19, P¼0.001), CD5 (FC: 2.38,
P¼0.009), and decreased expression of C7 (FC:-3.45, P¼0.001),
IL28B (FC:2.77, P¼0.003), and IL12RB1 (FC: -2.38, P¼0.004).
Between ﬂare and repeat biopsy, a 10-gene signature differentiated
ﬂares that ended in NR compared to CR and included increased
expression of IL17, IL1RAP, and iNOS and decreased expression of
NCAM1, and IL28B. Furthermore, neutrophil associated transcripts
(NCF4, LTF, CSF2RB, and CSF3R) and alternative complement
pathway component transcripts (increased C3, CFB, CFD and
decreased CFI, CD55, CD59) were more abundantly expressed in NR
biopsies compared to normal and CR biopsies with increasing
expression from Bx1 to Bx2 in the NR group.
Conclusions: These data suggest that the immunologic changes that
occur in a kidney biopsy after treatment of LN are different in ﬂares
that end in CR compared to NR. Increases in NCAM1 and IL28 may
predict response to treatment while increases in IL17 may reﬂect
non-response. Additionally, persistent neutrophil inﬁltration and
alternative pathway activation may play a role in preventing
response to standard therapy. Comparing the immunologic changes
within the kidney during successful and unsuccessful treatment
may identify novel therapeutic targets for LN and biomarkers of
response and non-response.
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Introduction: Injury in glomerulonephritis may be associated with
“proteotoxicity” due to protein misfolding, and induction of
endoplasmic reticulum (ER) stress and polyubiquitination. Exam-
ples include complement-induced glomerular epithelial cell (GEC)/
podocyte injury in membranous nephropathy, and focal segmental
glomerulosclerosis (FSGS). Podocyte injury due to proteotoxicity
can also result from mutations in integral proteins, which lead to
their misfolding and accumulation. We assessed if small molecule
modulators of proteostasis or accelerated removal of misfolded
proteins by the ubiquitin-proteasome system (UPS) can ameliorate
the proteotoxicity of misfolded proteins, using GEC culture and in
vivo models of glomerular injury.
Methods:We employed 4-phenylbutyric acid (4-PBA), a compound
that can improve protein folding by increasing the strength of
intramolecular hydrophobic bonds, or lowering a protein’s free
energy state, as well as celastrol, a drug that improves folding via
increasing expression of ER and cytosolic chaperones. Moreover, to
accelerate removal of misfolded proteins by the UPS, we employed
IU1, a compound that inhibits ubiquitin-speciﬁc protease 14
(Usp14), a deubiquitinating enzyme that retards proteasomal pro-
tein degradation.
Results: In cultured GECs stimulated with tunicamycin, 4-PBA
markedly reduced ER stress, as monitored by a reduction of stim-
ulated transcriptional activity of activating transcription factor-6
and reduction of stimulated expression of the ER chaperone, BiP.
Incubation of GECs with celastrol enhanced expression of BiP, heat-
shock protein (Hsp)-70, and transcriptional activity of heat shock
factor-1, which induces cytosolic chaperones, such as Hsp70. To
address complement cytotoxicity, GECs were incubated with anti-
body and serially-increasing doses of complement. This protocol
allows for complement to induce ER stress, but with increasing
incubation time and complement dose, a portion of the cells un-
dergoes lysis. Complement-mediated lysis in GECs was attenuated
signiﬁcantly by 4-PBA and celastrol. The UPS reporter proteins,
GFPu (a cytosolic “misfolded” protein) and CD3 (an ER-associated
degradation substrate) undergo time-dependent proteasomal
degradation in GECs. The Usp14 inhibitor, IU1, accelerated
the degradation of both misfolded reporter proteins by the pro-
teasome. IU1 did not, however, affect complement-induced GEC
cytotoxicity. The -actinin-4 K256E mutant, which induces FSGS in
humans, showed enhanced ubiquitination, formed aggregates, and
disrupted ER function in cultured GECs. 4-PBA and celastrol both
reduced -actinin-4 K256E aggregation. -actinin-4 K256E transgenic
mice develop podocyte injury, proteinuria and FSGS, in association
with glomerular ER stress. Treatment of these mice with 4-PBA in
the drinking water over a 10 week period signiﬁcantly reduced
albuminuria, and glomerular expression of the proapoptotic ER
stress protein, CHOP.
Conclusions: Podocyte injury associated with protein misfolding
was reduced by compounds that can improve protein folding either
directly or via enhanced expression of chaperones. Small molecule
proteostasis regulators may represent a novel therapeutic approach
to glomerulonephritis.
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Introduction: The clinical impact of anti-HLA antibodies is one of
the major area of research in renal allograft transplantation.
Luminex Platform has emerged as the favoured technology for
detection of HLA antibodies in addition to the CDC crossmatch
(XM). Luminex DSA crossmatch has been recently introduced in
India for detecting antibodies that are missed by CDC XM. We
present our experience with the Luminex based DSA crossmatch
test done in the recipients who underwent transplantation at Sir
Ganga Ram Hospital in the year 2013-14 with one year post
transplant follow up. The objective of the study was to evaluate the
impact of the pre-Tx DSAs detected by Luminex crossmatch on the
clinical outcome of the renal graft over a period of one year
Methods: We began performing DSA (donor speciﬁc antibody)
monitoring protocol by Luminex in the year 2013 at our center. The
present study includes patients from January 2013 to December
2013 with one year follow up post kidney transplant. Pre- trans-
plant sera from 46 renal transplant recipients with a negative CDC
crossmatch were assessed for donor-speciﬁc antibodies (DSA)
detection on Luminex Platform using Lifecodes DSA kit (Immucor).
The serum samples with DSA (HLA-Class I or II or both) of MFI
(mean ﬂuorescent intensity) value more than 500 was considered to
be positive. The results were then correlated with the clinical
outcomes of the renal allograft.
Results: SAs were found in 11 out of 46 recipients (23.9%). Of the
eleven DSA positive patients, 3 patients (27.27%) developed acute
graft rejection. All these 3 patients had positive C4d staining in
their biopsies and the MFI value of the DSA on Luminex platform
was found to be more than 1000. The remaining 8 DSA positive
patients showed no rejection and had stable graft function. The MFI
value of the DSAs in these patients ranged from 500-1000. All the
35 DSA negative patients (76.1%) were also having stable graft
function in one year follow up. Hence, AMR was more frequent in
the DSA positive group than in DSA negative group. outcome of the
renal graft over a period of one year.
Conclusions: The present study evaluates the importance of
Luminex DSA crossmatch test in detecting the donor speciﬁc HLA
antibodies over the CDC crossmatch. There was a higher incidence
of AMR in patients with pre-transplant DSA despite a negative CDC
crossmatch. The present study clearly establishes that the Luminex
DSA crossmatch is helpful for predicting post transplant graft
outcome or rejection. The laboratory cut off value of the MFI for
positive DSA was increased from 500 to 1000. We suggest that DSA
MFI value above 1000 should be considered for further evaluation
by Single antigen bead assay (SAB) by Luminex. However, the
clinical impact of the pre-Tx DSAs detected by Luminex techniques
has to be fully evaluated in terms of graft survival and more
retrospective studies with larger sample size.
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common end-point of progressive kidney diseases. A multitude of
factors and processes were found to promote and aggravate renal
ﬁbrosis, but our understanding of endogenous factors limiting
ﬁbrosis is limited.
Methods: Here we analyzed the role of macrophage migration
inhibitory factor (MIF), a pleiotropic proinﬂammatory cytokine, in
animal models of renal tubulointerstitial ﬁbrosis and inﬂammation.
Results: We show that MIF expression is reduced in murine and
human renal tubulointerstitial ﬁbrosis. MIF inhibition using gene
knock-out, neutralizing antibodies or a small-molecule inhibitor
aggravated ﬁbrosis and worsened parameters of renal function,
while treatment with murine recombinant MIF abrogated renal
ﬁbrosis. This effect was consistent in three distinct models of renal
ﬁbrosis, i.e. those induced by obstruction, ischemia-reperfusion or
toxin, and was also effective when treatment was initiated in
already established ﬁbrosis. Bone-marrow chimeras showed that
local but not bone-marrow derived MIF was involved. Mechanis-
tically, MIF reduced the expression of chemokine MCP-1 in tubular
cells and reduced renal inﬂammatory inﬁltrates already early in
disease.
Conclusions: Taken together, we identiﬁed a hitherto unappreci-
ated role of MIF as an endogenous factor limiting renal tubu-
lointerstitial ﬁbrosis via limiting renal inﬂammation. Our data raise
important safety concerns regarding the envisaged use of MIF in-
hibition as a treatment for inﬂammatory diseases.
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Introduction: MPO-ANCA-associated vasculitis (MPO-AAV) is a
systemic small vessel vasuculitis that involves preferentially the
kidneys. It has been shown the pathogenic role of MPO-ANCA in
MPO-AAV. Neutrophil extracellular traps (NETs), which are
released from neutrophils activated by microorganisms, are
composed of net-like chromatin ﬁbers and antimicrobial proteins,
such as MPO. The activated neutrophils die in due course with the
formation of NETs. During the NET formation, histones bound
chromatin ﬁbers are citrullinated by peptigylarginine deiminase 4
(PAD4), and consequently the chromatin ﬁbers are decondensated.
Thus, PAD4 plays a pivotal role in the NET formation. Although
NETs are essential for elimination of microorganisms, excessive
formation of NETs has been shown to be implicated in the MPO-
ANCA production. The aim of this study is to determine that in-
hibition of PAD4 can suppress the NET formation and MPO-ANCA
production in vivo.
Methods: According to our previous report, NETs were induced in
peripheral blood neutrophils derived from healthy donors (1106/
ml) by stimulation with 20 nM phorbol myristate acetate (PMA)
with or without 20 mM anti-thyroid drug, propylthiouracil (PTU)
for 2 hours at 37 oC. The effect of PAD4 inhibitor, 200 mM Cl-
amidine, on the in vitro NET formation induced by 20 nM PMAS7
